U.S. study on 32,449 people shows AstraZeneca vaccine offers 100% protection against severe disease
Some 32,449 people across all age groups took part in the phase three trial in the U.S., Chile and Peru, with a total of 141 cases of symptomatic Covid-19 reported.
The Oxford/AstraZeneca vaccine is 79% effective at preventing COVID-19 and offers 100% protection against severe disease, new data has shown.
The early findings from the U.S. study are just one set of information AstraZeneca must submit to the Food and Drug Administration.
The results showed that among people aged 65 and over, there was 80% protection against developing Covid-19.
The degree of effectiveness for the jab was even higher than observed in the Oxford-led clinical trials.
An independent data safety monitoring board (DSMB) also identified no safety concerns related to the vaccine.
It conducted a specific review of thrombotic events, as well as cerebral venous sinus thrombosis (CVST) – the specific type of brain blood clot that has been troubling Europe.
The DSMB found no increased risk of thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no cases in this trial. ■